Pegvisomant Pfizer/Sensus

Curr Opin Investig Drugs. 2004 Apr;5(4):463-8.

Abstract

Pfizer (formerly Pharmacia), in collaboration with its wholly owned subsidiary Sensus, has developed and launched pegvisomant, a pegylated, genetically modified human growth hormone (hGH), for the treatment of acromegaly. Pegvisomant, in contrast to classical somatostatin analogs which lower hGH synthesis, exerts its anti-hGH action by preventing GH receptor activation. This drug is now available in the US and Europe for the treatment of acromegaly.

Publication types

  • Review

MeSH terms

  • Acromegaly / drug therapy
  • Animals
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Delayed-Action Preparations
  • Human Growth Hormone / analogs & derivatives*
  • Human Growth Hormone / chemistry*
  • Human Growth Hormone / pharmacology
  • Human Growth Hormone / therapeutic use
  • Humans
  • Injections, Subcutaneous
  • Receptors, Somatotropin / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Delayed-Action Preparations
  • Receptors, Somatotropin
  • Human Growth Hormone
  • pegvisomant